New Study Elucidates Obesity’s Role in Fueling Breast Cancer Progression

Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, revealing how leptin, a hormone produced by fat cells, signals cancer cells to grow. This leads to increased activity of the enzyme stearoyl-CoA desaturase (SCD), which fuels the growth and motility of cancer cells. The findings from a studyopens in new tab/window in The American Journal of Pathologyopens in new tab/window, published by Elsevier, provides insights into the obesity–breast cancer link and identifies potential new therapeutic targets to counter obesity-driven breast cancer progression.

According to the World Obesity Federation’s 2025 Atlas, the global number of adults living with obesity is projected to reach 1.13 billion by 2030. Given the well-established epidemiological link between obesity and breast cancer, elucidating the molecular mechanisms underlying this association has become a major research priority.

“By integrating transcriptomic, lipidomic, and functional analyses, we uncovered a crucial role of the leptin-SCD axis in breast cancer biology,” explains lead investigator of the study Ines Barone, PhD, of the University of Calabria, Italy. “Our data indicate that the combined upregulation of leptin and SCD identifies a subgroup of breast cancers with poorer recurrence-free survival. This metabolic signature could serve as a prognostic marker, helping to stratify patients according to obesity-related metabolic risk.”

The researchers found that blocking SCD activity abolished leptin-induced oncogenic traits, such as enhanced cell growth, motility, mitochondrial respiration, and adenosine triphosphate (ATP) molecule production. Together, these findings provide a mechanistic explanation for how obesity can fuel hormone-responsive breast cancer progression.

Dr. Barone concludes, “We were fascinated to see that selectively blocking SCD could almost completely counteract the pro-tumorigenic effects driven by leptin, revealing a striking vulnerability in this pathway. Our findings hold promise for patients with estrogen receptor-positive breast cancer, the most common subtype of breast cancer, as targeting SCD could limit disease progression in obese breast cancer patients.”

Notes for editors

The article is “Interplay between Leptin and Stearoyl-CoA Desaturase 1 in Estrogen Receptor—Positive Breast Cancer Cells,” by Felice Maria Accattatis, Luca Gelsomino, Linda Manna, Piercarlo Del Console, Laura Bianchi, Alfonso Carleo, Rossana De Salvo, Lorenzo Arnaboldi, Ludovica Baù, Alberto Corsini, Adele E. Leonetti, Rocco Malivindi, Marco Fiorillo, Michael P. Lisanti, Cinzia Giordano, Daniela Bonofiglio, Sebastiano Andò, Stefania Catalano, and Ines Barone (https://doi-org.ucc.idm.oclc.org/10.1016/j.ajpath.2025.08.009opens in new tab/window). It appears in The American Journal of Pathology, volume 195, issue 12 (December 2025), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(25)00336-0/fulltextopens in new tab/window.

The authors would like to acknowledge that this work was the result of a true team effort involving multiple complementary skills from multiple universities: molecular biology (University of Calabria and University of Salford), lipidomics (University of Milan), and bioinformatics (University of Siena). Each group contributed to a different aspect of the study, and their combined efforts highlight both the interdisciplinary nature and the strength of this research.

This study was supported by the European Union’s NextGenerationEU initiative under the Italian Ministry of University and Research and by the Italian Association for Cancer Research (AIRC).

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors, contact Stefania Catalano, MD, at [email protected]opens in new tab/window or Ines Barone, PhD, at [email protected]opens in new tab/window.

About The American Journal of Pathology

The American Journal of Pathologyopens in new tab/window, official journal of the American Society for Investigative Pathologyopens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.